PDCD1 and colorectal carcinoma: However, up to 50% of patients with advanced MMRd stage IV colorectal cancer (CRC) do not respond to PD-1 blockade, highlighting the need to explore resistance mechanisms impacting the success of checkpoint blockade 11,12.